Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Open access
Pomeroy, Emily J., Hunzeker, John T., Kluesner, Mitchell G., Lahr, Walker S., Smeester, Branden A., Crosby, Margaret R., Lonetree, Cara-lin, Yamamoto, Kenta, Bendzick, Laura, Miller, Jeffrey S., Geller, Melissa A., Walcheck, Bruce, Felices, Martin, Webber, Beau R., Starr, Timothy K., Moriarity, Branden S.·2020·Molecular Therapy

Abstract

Enhancing natural killer (NK) cell cytotoxicity by blocking inhibitory signaling could lead to improved NK-based cancer immunotherapy. Thus, we have developed a highly efficient method for editing the genome of human NK cells using CRISPR/Cas9 to knock out inhibitory signaling molecules. Our method efficiently edits up to 90% of primary peripheral blood NK cells. As a proof-of-principle we demonstrate highly efficient knockout of ADAM17 and PDCD1, genes that have a functional impact on NK cells, and demonstrate that these gene-edited NK cells have significantly improved activity, cytokine production, and cancer cell cytotoxicity. Furthermore, we were able to expand cells to clinically relevant numbers, without loss of activity. We also demonstrate that our CRISPR/Cas9 method can be used for efficient knockin of genes by delivering homologous recombination template DNA using recombinant adeno-associated virus serotype 6 (rAAV6). Our platform represents a feasible method for generating engineered primary NK cells as a universal therapeutic for cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2019.10.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 195

Metadata

Authors
Pomeroy, E. J., Hunzeker, J. T., Kluesner, M. G., Lahr, W. S., Smeester, B. A., Crosby, M. R., Lonetree, C.-L., Yamamoto, K., Bendzick, L., Miller, J. S., Geller, M. A., Walcheck, B., Felices, M., Webber, B. R., Starr, T. K., & Moriarity, B. S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2020-01
Volume
28
Issue
1
Pages
52-63
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2980981340
Cited by
195
References
3
FWCI
7.37
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. https://app.cochat.ai/papers/10.1016/j.ymthe.2019.10.009
The paper
Pomeroy, E. J., Hunzeker, J. T., Kluesner, M. G., Lahr, W. S., Smeester, B. A., Crosby, M. R., Lonetree, C.-L., Yamamoto, K., Bendzick, L., Miller, J. S., Geller, M. A., Walcheck, B., Felices, M., Webber, B. R., Starr, T. K., & Moriarity, B. S. (2020). A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2019.10.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.